Video
The success of cellular therapies in patients with SUI
Author(s):
Video Player is loading.
In this video, Melissa R. Kaufman, MD, PhD, FACS, discusses the takeaways from the study, “A double-blind, randomized, controlled trial comparing safety and efficacy of autologous muscle derived cells for urinary sphincter repair (AMDC-USR) with placebo (PBO) in women with stress urinary incontinence (SUI),” presented during the 2021 American Urological Association annual meeting. Kaufman is a professor of urology and chief of the division of reconstructive urology and pelvic health at Vanderbilt University, Nashville, Tennessee.
Related Videos
Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
Optimizing onabotA for OAB: What are some common misconceptions?
Ruchika Talwar, MD, on how urologists can get involved in advocacy
Investigators characterize vibegron prescribing patterns for OAB
Ruchika Talwar, MD, discusses ongoing drug shortages in urology
Expert outlines advantages of batteryless sacral neuromodulation device
Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
Smaller size, patient control advantages of neurostimulator for OAB
Batteryless neurostimulator found efficacious at 6-month follow-up
Related Content
